keyword
MENU ▼
Read by QxMD icon Read
search

noac hemorrhagic risk

keyword
https://www.readbyqxmd.com/read/27893153/efficacy-and-safety-of-dabigatran-rivaroxaban-and-warfarin-for-stroke-prevention-in-chinese-patients-with-atrial-fibrillation-the-hong-kong-atrial-fibrillation-project
#1
Wen-Hua Li, Duo Huang, Chern-En Chiang, Chu-Pak Lau, Hung-Fat Tse, Esther W Chan, Ian C K Wong, Gregory Y H Lip, Pak-Hei Chan, Chung-Wah Siu
BACKGROUND: Little is known about the comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOAC) compared to warfarin in Chinese atrial fibrillation (AF) patients. Our aim was to compare the ischemic stroke risk reduction and incidence of intracranial hemorrhage (ICH) of warfarin in relation to quality of anticoagulation control (as reflected by time in therapeutic range [TTR]), and to dabigatran and rivaroxaban in a real-world cohort of Chinese AF patients...
November 28, 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/27777713/medication-error-when-switching-from-warfarin-to-rivaroxaban-leading-to-spontaneous-large-ecchymosis-of-the-abdominal-and-chest-wall
#2
Flavio Egger, Federica Targa, Ivan Unterholzner, Russell P Grant, Markus Herrmann, Christian J Wiedermann
Non-vitamin K oral anticoagulant (NOAC) therapy may be inappropriate if prescription was incorrect, the patient's physiological parameters change, or interacting concomitant medications are erroneously added. The aim of this report was to illustrate inappropriate NOAC prescription in a 78-year-old woman with non-valvular atrial fibrillation and borderline renal dysfunction who was switched from warfarin to rivaroxaban and subsequently developed bruising with hemorrhagic shock and acute on chronic renal failure...
August 8, 2016: Clinics and Practice
https://www.readbyqxmd.com/read/27659468/atrial-fibrillation-and-thromboembolism-in%C3%A2-patients-with-chronic-kidney-disease
#3
REVIEW
Yee C Lau, Marco Proietti, Elisa Guiducci, Andrew D Blann, Gregory Y H Lip
A bidirectional relationship exists between atrial fibrillation (AF) and chronic renal disease. Patients with AF have a higher incidence of renal dysfunction, and the latter predisposes to incident AF. The coexistence of both conditions results in a higher risk for thromboembolic-related adverse events but a paradoxical increased hemorrhagic risk. Oral anticoagulants (both vitamin K antagonists [VKAs] and non-VKA oral anticoagulants [NOACs]) have been demonstrated to be effective in mild to moderate renal dysfunction...
September 27, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27614940/efficacy-and-safety-of-novel-oral-anticoagulants-in-patients-with-atrial%C3%A2-fibrillation-and-heart-failure-a-meta-analysis
#4
Gianluigi Savarese, Robert P Giugliano, Giuseppe M C Rosano, John McMurray, Giulia Magnani, Gerasimos Filippatos, Santo Dellegrottaglie, Lars H Lund, Bruno Trimarco, Pasquale Perrone-Filardi
OBJECTIVES: This study investigated the efficacy and safety of novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and heart failure (HF) by a meta-analysis. BACKGROUND: AF is quite prevalent in patients with HF. METHODS: Four phase III clinical trials comparing NOACs to warfarin in patients with AF were included. Each patient was defined as affected by HF according to the criteria of the trial in which the patient was enrolled...
August 28, 2016: JACC. Heart Failure
https://www.readbyqxmd.com/read/27582891/novel-oral-anticoagulants-for-the-secondary-prevention-of-cerebral-ischemia-a-network-meta-analysis
#5
Aristeidis H Katsanos, Dimitris Mavridis, John Parissis, Spyridon Deftereos, Alexandra Frogoudaki, Agathi-Rosa Vrettou, Ignatios Ikonomidis, Maria Chondrogianni, Apostolos Safouris, Angeliki Filippatou, Konstantinos Voumvourakis, Nikos Triantafyllou, John Ellul, Theodore Karapanayiotides, Sotirios Giannopoulos, Anne W Alexandrov, Andrei V Alexandrov, Georgios Tsivgoulis
BACKGROUND: Novel oral anticoagulants (NOACs) have shown to be both safe and effective for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). We conducted a network meta-analysis (NMA) using published data from secondary prevention subgroups of different phase III randomized clinical trials (RCTs) comparing individual NOACs with warfarin. METHODS: Eligible studies were identified by searching MEDLINE and SCOPUS and the Cochrane Central Register of Controlled Trials databases...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27556937/pathogenesis-diagnosis-and-treatment-of-venous-thromboembolism-in-older-adults
#6
Stacy A Johnson, G Paul Eleazer, Matthew T Rondina
Older adults have a significantly greater risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, than younger adults. The cause of this greater risk is thought to be multifactorial, including age-related changes in hemostatic factors and greater comorbid conditions and hospitalizations, but is not completely understood. Moreover, VTE remains underrecognized in older adults and may present atypically. Thus, a low index of clinical suspicion is essential when evaluating older adults with possible VTE...
September 2016: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/27545637/-new-oral-anticoagulants-noac-in-nephrology
#7
Antonio Bellasi, Luca Di Lullo, Gianvincenzo Melfa, Claudio Minoretti, Carlo Ratti, Carlo Campana, Maurizio Volpi, Stefano Mangano, Biagio Di Iorio, Mario Cozzolino
The new or direct oral anticoagulants [new oral anticoagulants (NOAC) or direct oral anticoagulants (DOAC)] were launched in the Italian market in 2013. Although these compounds share common pharmacological indications with vitamin K antagonists (warfarin or acenocumarol), they have different mechanisms of action, do not require a constant anticoagulant monitoring but are more efficacious and safer than vitamin K antagonists. The use of these molecules (Dabigatran, Apixaban, Rivaroxaban, Betrixaban, Edoxaban) is constantly rising in daily practice...
July 2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/27533256/stroke-prevention-in-atrial-fibrillation-focus-on-latin-america
#8
Ayrton R Massaro, Gregory Y H Lippp
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an estimated prevalence of 1-2% in North America and Europe. The increased prevalence of AF in Latin America is associated with an ageing general population, along with poor control of key risk factors, including hypertension. As a result, stroke prevalence and associated mortality have increased dramatically in the region. Therefore, the need for effective anticoagulation strategies in Latin America is clear. The aim of this review is to provide a contemporary overview of anticoagulants for stroke prevention...
August 11, 2016: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/27477399/the-efficacy-and-safety-of-oral-rivaroxaban-in-patients-with-non-valvular-atrial-fibrillation-scheduled-for-electrical-cardioversion
#9
Yoshinari Enomoto, Naoshi Ito, Tadashi Fujino, Mahito Noro, Takanori Ikeda, Kaoru Sugi
Objective Electrical cardioversion (EC) is associated with an increased risk of thrombotic events in patients with non-valvular atrial fibrillation (NVAF). Patients who experience AF for a period of >48 hours therefore require adequate anticoagulation therapy for at least 3 weeks before and 4 weeks after EC. While the guidelines address the management of vitamin K antagonists (VKAs), there are limited data on the use of novel oral anticoagulants (NOAC). One NOAC, rivaroxaban, has a rapid onset of action and might therefore shorten the time for which anti-coagulant treatment is required before a patient undergoes EC...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27394924/vitamin-k-and-non-vitamin-k-antagonist-oral-anticoagulants-for-non-valvular-atrial-fibrillation-in-real-life
#10
Michela Giustozzi, Maria Cristina Vedovati, Paolo Verdecchia, Lucia Pierpaoli, Melina Verso, Serenella Conti, Federica Cianella, Emanuela Marchesini, Esmeralda Filippucci, Giancarlo Agnelli, Cecilia Becattini
BACKGROUND: Current guidelines recommend vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF). METHODS: We compared the clinical features of consecutive in- and out-patients with non-valvular AF newly-treated with NOACs or on treatment with VKAs. RESULTS: Overall, 1314 patients newly-treated with NOACs and 1024 on treatment with VKAs were included in the study...
September 2016: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/27311528/nonvitamin-k-anticoagulant-agents-in%C3%A2-patients-with-advanced-chronic-kidney%C3%A2-disease-or-on-dialysis-with-af
#11
REVIEW
Kevin E Chan, Robert P Giugliano, Manesh R Patel, Stuart Abramson, Meg Jardine, Sophia Zhao, Vlado Perkovic, Franklin W Maddux, Jonathan P Piccini
Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce stroke, intracranial hemorrhage, and mortality, with lower to similar major bleeding rates compared with warfarin. All NOACs are dependent on the kidney for elimination, such that patients with creatinine clearance <25 ml/min were excluded from all the pivotal phase 3 NOAC trials. It therefore remains unclear how or if NOACs should be prescribed to patients with advanced chronic kidney disease and those on dialysis...
June 21, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27292781/developments-of-anticoagulants-and-new-agents-with-anti-coagulant-effects-in-deep-vein-thrombosis
#12
Yi-Ping Dang, Yun-Fei Chen, Yi-Qing Li, Lei Zhao
Deep Vein Thrombosis (DVT) has been known as a common medical problem all over the world. Thrombus traveling in blood vessels may lead to pulmonary embolism (PE), associated with high rates of mortality. Anticoagulant therapy is the mainstay treatment of DVT. Common anticoagulants, Vitamin K antagonists (VKAs) unfractionated heparin (UFH) and Low-molecular-weight heparin (LMWH) have been used in clinical application over decades, but can increase the risk of hemorrhage. Thereby, several new oral anticoagulants (NOACs) have been developed, which includes direct thrombin inhibitors (DTI) and direct factor Xa inhibitors...
June 8, 2016: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/27262782/efficacy-and-safety-of-non-vitamin-k-antagonist-oral-anticoagulants-after-cardioversion-for-nonvalvular-atrial-fibrillation
#13
Giulia Renda, Marco Zimarino, Fabrizio Ricci, Jonathan P Piccini, Michael D Ezekowitz, Manesh R Patel, Riccardo Cappato, Robert P Giugliano, Raffaele De Caterina
BACKGROUND: Non-vitamin K oral anticoagulants (NOACs) are proven alternatives to vitamin K antagonists (VKAs) for the prevention of thromboembolism in patients with nonvalvular atrial fibrillation. However, there are few data on the efficacy and safety of NOAC therapy after cardioversion, where the risk of thromboembolic events is heightened. METHODS: We performed a random-effects meta-analysis of patients who underwent both electrical and pharmacologic cardioversion for atrial fibrillation in the RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48, and X-VeRT trials...
October 2016: American Journal of Medicine
https://www.readbyqxmd.com/read/27247481/update-on-anticoagulation-what-the-interventional-radiologist-needs-to-know
#14
REVIEW
Suneel D Kamath, Brandon J McMahon
The novel oral anticoagulants (NOACs) represent a major advance in the treatment of patients with nonvalvular atrial fibrillation and venous thromboembolism (VTE). They have several advantages over vitamin-K antagonists such as warfarin, including more predictable pharmacokinetics and improved safety, particularly with fatal bleeding and intracranial hemorrhage. However, several issues remain surrounding the use of NOACs in certain subpopulations and with the approach to reversal. The periprocedural management of anticoagulation with these relatively new agents can also present several challenges...
June 2016: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/27243343/management-of-patients-with-atrial-fibrillation-and-chronic-kidney-disease-in-light-of-the-latest-guidelines
#15
Elżbieta Młodawska, Anna Tomaszuk-Kazberuk, Paulina Łopatowska, Włodzimierz J Musiał, Jolanta Małyszko
Atrial fibrillation (AF) frequently occurs in patients with chronic kidney disease (CKD), and the rate reaches even 30% in patients with end-stage renal disease (ESRD). Patients with AF and CKD have a significantly higher risk of thrombotic complications, particularly ischemic stroke, and at the same time, a higher bleeding risk (proportionally to the grade of renal failure). In addition, AF and CKD share a number of comorbidities and risk factors, which results in increased mortality rates. Moreover, disturbances in hemostasis are common complications of kidney disease...
May 31, 2016: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/27207998/comparative-effectiveness-of-interventions-for-stroke-prevention-in-atrial-fibrillation-a-network-meta-analysis
#16
Larisa G Tereshchenko, Charles A Henrikson, Joaquin Cigarroa, Jonathan S Steinberg
BACKGROUND: The goal of this study was to compare the safety and effectiveness of individual antiembolic interventions in nonvalvular atrial fibrillation (AF): novel oral anticoagulants (NOACs) (apixaban, dabigatran, edoxaban, and rivaroxaban); vitamin K antagonists (VKA); aspirin; and the Watchman device. METHODS AND RESULTS: A network meta-analysis of randomized, clinical trials (RCTs) was performed. RCTs that included patients with prosthetic cardiac valves or mitral stenosis, mean or median follow-up <6 months, <200 participants, without published report in English language, and NOAC phase II studies were excluded...
May 20, 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27207691/safety-and-efficacy-of-non-vitamin-k-oral-anticoagulant-treatment-compared-with-warfarin-in-patients-with-non-valvular-atrial-fibrillation-who-develop-acute-ischemic-stroke-or-transient-ischemic-attack-a-multicenter-prospective-cohort-study-davinci-study
#17
Naoki Saji, Kazumi Kimura, Yohei Tateishi, Shigeru Fujimoto, Nobuyuki Kaneko, Takao Urabe, Akira Tsujino, Yasuyuki Iguchi
The safety and efficacy of non-vitamin K oral anticoagulant (NOAC) compared with warfarin in treating patients with non-valvular atrial fibrillation (NVAF) who developed acute ischemic stroke or transient ischemic attack (AIS/TIA), particularly those receiving tissue-plasminogen activator (tPA) therapy, remains unclear. Between April 2012 and December 2014, we conducted a multicenter prospective cohort study to assess the current clinical practice for treating such patients. We divided the patients into two groups according to the administration of oral anticoagulants (warfarin or NOACs) and tPA therapy...
November 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/26969761/use-of-oral-anticoagulants-for-stroke-prevention-in-patients-with-atrial-fibrillation-who-have-a-history-of-intracranial-hemorrhage
#18
Tze-Fan Chao, Chia-Jen Liu, Jo-Nan Liao, Kang-Ling Wang, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Fa-Po Chung, Tzeng-Ji Chen, Gregory Y H Lip, Shih-Ann Chen
BACKGROUND: The risk of further intracranial hemorrhage (ICH) and the benefit of stroke risk reduction with the use of oral anticoagulants for patients who have atrial fibrillation with a history of ICH remain unclear. We aimed to investigate the risks and benefits in patients who have atrial fibrillation with a previous ICH treated with warfarin or antiplatelet drugs in comparison with no antithrombotic therapies. METHODS AND RESULTS: This study used the National Health Insurance Research Database in Taiwan...
April 19, 2016: Circulation
https://www.readbyqxmd.com/read/26965066/-apixaban-related-convexal-subarachnoid-hemorrhage-a-case-report
#19
Kiyoharu Shimizu, Kiyoshi Yuki, Takashi Sadatomo, Takeshi Hara, Hideo Ohba, Kaoru Kurisu
The risk of anticoagulant-associated intracranial hemorrhage(ICH)is relatively low in patients treated with non-vitamin K antagonist oral anticoagulants(NOAC). The anticoagulant-associated ICH comprises mainly intraparenchimal hemorrhage. Subdural hematoma and subarachnoid hemorrhage(SAH)are rare complications after treatment with NOAC, trauma being the most common cause for these two types of ICH. We report a case of non-traumatic convexal SAH(cSAH)associated with Apixavan. A 68-year-old man with repeated history of cerebral embolism with cardiogenic cause presented with weakness of the lower limbs...
March 2016: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/26923792/challenges-and-treatment-for-stroke-prophylaxis-in-patients-with-atrial-fibrillation-in-mexico-a-review
#20
REVIEW
Luis Alcocer
Atrial fibrillation (AF) is associated with an increased risk of stroke. AF-related strokes cause greater disability and mortality than those in patients without AF, and are associated with a significant clinical and economic burden in Mexico. Antithrombotic therapy reduces stroke risk in patients with AF and is recommended for all patients except those classified as having a low stroke risk. However, its use is suboptimal all around the world; one study showed that only 4 % of Mexican patients with AF who presented with ischemic stroke were in the therapeutic range for anticoagulation...
June 2016: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
keyword
keyword
88350
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"